Mode
Text Size
Log in / Sign up
N/A N=100 Randomized Treatment

EDWARDS INTUITY Valve System CADENCE-MIS Study

Aortic Valve Disease · Aortic Stenosis

Enrolled (actual)
100
Serious AEs
59.8%
Results posted
Jan 2019
Primary outcome: Primary: Median Subject Time Spent on Cardiopulmonary Cross Clamp — 35.0; 47.5 Minutes — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
EDWARDS INTUITY Valve System, Model 8300A (Device); Stented Aortic Bioprostheses (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Edwards Lifesciences
Primary completion
Mar 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Median Subject Time Spent on Cardiopulmonary Cross Clamp
35.0; 47.5 <0.0001 sig
PRIMARY
Median Amount of Time Subject Spent on Cardiopulmonary Bypass
58.5; 69.0 0.2077
SECONDARY
Number of Participants With Change From Baseline in New York Heart Association (NYHA) Class at 2 Years.
22; 27; 17; 11; 1; 1
SECONDARY
Subject's Average Mean Gradients (mmHg) Measurements Over Time.
44.0; 45.4; 10.3; 10.8; 8.8; 9.7
SECONDARY
Subject's Average Peak Gradients (mmHg) Measurements Over Time.
69.6; 75.4; 19.0; 21.0; 16.5; 17.8
SECONDARY
Subject's Effective Orifice Area (EOA) Measurement Over Time.
0.7; 0.7; 1.9; 1.9; 1.9; 2.0
SECONDARY
Amount of Paravalvular Leak Over Time.
30; 33; 10; 7; 1; 3
SECONDARY
Conversion of Edwards INTUITY Surgical Aortic Valve to Control Surgical Aortic Heart Valves During Surgery.
3; 0
SECONDARY
Subjects Who Required a Thoracic Resternotomy Over Time
6; 5; 6; 5; 7; 5
SECONDARY
Subjects Who Received a Permanent Pacemaker Over Time.
2; 1; 2; 1; 2; 1
SECONDARY
Subjects With a Paravalvular Leak > or Equal to 3+ and/or Requiring Intervention Over Time
0; 1; 0; 1; 2; 1
SECONDARY
Subjects Who Experienced Major Bleeding Over Time.
8; 4; 8; 5; 8; 5
SECONDARY
Subjects Who Experienced Respiratory Failure Over Time
2; 0; 2; 0; 2; 2
SECONDARY
Subjects With a Cerebral Vascular Accident or Permanent Stroke Over Time
2; 2; 2; 2; 2; 2
SECONDARY
Subjects With Renal Failure Over Time
3; 0; 3; 0; 3; 1
SECONDARY
Subjects With Endocarditis Over Time
0; 0; 0; 0; 0; 0
SECONDARY
Subjects With a Deep Sternal Would Infection Over Time
1; 1; 1; 1; 1; 1
SECONDARY
Subjects With a Myocardial Infarction Over Time
0; 1; 0; 1; 0; 2
SECONDARY
Subjects With a Thromboembolism Over Time
3; 3; 3; 3; 4; 4
SECONDARY
Subjects With a Cardiac Tamponade Over Time
2; 3; 2; 3; 2; 3
SECONDARY
Subjects With a Cardiac Reoperation for Any Reason Over Time
6; 5; 6; 5; 7; 6
SECONDARY
Conversion of Subjects Undergoing Minimally Invasive Surgical Incision to Full Sternotomy for the Randomized to Edwards INTUITY Group During Surgery.
0; 0
SECONDARY
Subject's Average Score on the EQ-5D - Quality of Life Questionnaire Over Time
0.900; 0.902; 0.862; 0.902; 0.908; 0.918
SECONDARY
Subject's Average Score SF-12 - Quality of Life Questionnaire Over Time
42.39; 40.79; 36.16; 38.45; 41.42; 43.95
SECONDARY
Subject's Average Score on the KCCQ - Quality of Life Questionnaire Over Time
58.37; 61.33; 57.81; 64.33; 69.32; 76.35
SECONDARY
Health Care Utilization
10.9; 11.5; 2.6; 1.6; 1.3; 0.9
SECONDARY
Subject's Effective Orifice Area Index (EOAI) Measurement Over Time.
0.4; 0.4; 0.9; 1.0; 1.0; 1.1
SECONDARY
Amount of Aortic Valvular Regurgitation Over Time.
29; 29; 10; 13; 1; 2

Summary

The study purpose is to compare the EDWARDS INTUITY valve system in a minimal invasive surgical approach (MIS) with any commercially available aortic bioprosthesis in standard full sternotomy surgical approach.

Eligibility Criteria

Inclusion:

  • adult male or female ≥18 years of age
  • symptomatic for aortic stenosis / mixed aortic stenosis and aortic insufficiency disease for which isolated surgical aortic valve replacement without concomitant procedures is planned
  • EuroSCORE <20
  • NYHA Class ≥II
  • Subject has signed and dated the investigation informed consent form prior to study specific procedures are performed
  • Subject is geographically stable and agrees to participate in follow-up assessments as specified in the protocol and informed consent

Exclusion (i.a.):

  • pure aortic insufficiency
  • previous cardiac surgery (involved FS or MIS approach)
  • congenital true bicuspid / unicuspid aortic valve
  • requires emergency surgery or has had emergency surgery for any reason

≤ 1 month before the intended treatment

  • LVEF <25%
  • active endocarditis ≤ 6 months before the intended treatment
  • acute MI ≤ 90 days before the intended treatment
  • had a stroke or transient ischemic attack within six months prior to scheduled aortic valve replacement surgery
  • oxygen or ventilator dependent
  • life expectancy < 12 months
  • substance abuser
  • Female subject is pregnant or lactating
  • documented leukopenia (WBC < 3.5x 103/μL), acute anemia (Hgb < 10.0 gm/dL or < 6.2 mmol/L), thrombocytopenia (platelet count < 100x 103/mL), or history of bleeding diathesis or coagulopathy
  • hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days of procedure
  • documented echocardiographic evidence of intracardiac mass, thrombus or vegetation
  • renal insufficiency as determined by Serum creatinine ≥ 200 μmol/L (2.27 mg/dL) at screening or end-stage renal disease requiring chronic dialysis
  • documented hyperparathyroidism
  • currently participating in an investigational drug or device trial for which follow-up has not yet been completed
  • Minimally Invasive access to the heart is not possible due to anatomical constraints or any other pre-existing condition

Intra-operative Exclusion:

  • has calcium on the anterior mitral leaflet which cannot be removed
  • has extensive calcification of the aortic root
  • Annular deformation which may or may not be caused by too extensive decalcification of the aortic annulus
  • has left atrial thrombus
  • The position of the coronary ostia relative to the EDWARDS INTUITY Valve would result in obstruction of blood flow
  • hemodynamically unstable during the procedure requiring the procedure to be aborted prior to insertion of the study bioprosthesis and delivery system
  • Study device is not available in the correct size for the subject
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02672553). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search